Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06482554
PHASE3

Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.

Sponsor: Louisiana State University Health Sciences Center Shreveport

View on ClinicalTrials.gov

Summary

This study is looking to determine if Lumateperone improves motivation in patients with schizophrenia or schizoaffective disorders who show high levels of apathy as judged by AES-C-Apathy (Apathy Evaluation Scale - Clinician - Apathy) assessment and to examine a possible correlation between improvement in apathy scores and changes in elements of the PANSS (Positive and Negative Syndrome Scale) due to treatment with Lumateperone.

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

80

Start Date

2024-06

Completion Date

2026-12

Last Updated

2024-07-01

Healthy Volunteers

No

Interventions

DRUG

Lumateperone 42 mg

Standard treatment with lumateperone

DRUG

Risperidone 2 mg

Standard treatment with other antipsychotic drugs

Locations (1)

LSU Health Shreveport

Shreveport, Louisiana, United States